Le Lézard
Classified in: Health
Subject: CALENDAR OF EVENTS

PRA Health Sciences to Report Second Quarter 2018 Earnings


RALEIGH, N.C., July 12, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter results after the market closes on Wednesday, August 1, 2018. The Company will also host a conference call on Thursday, August 2, 2018 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 9692658. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 9692658.

A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio playback of the call will be available at the same website.

ABOUT PRA HEALTH SCIENCES

PRA Health Sciences is a full service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA's integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting.  PRA's global operations span more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: [email protected]


These press releases may also interest you

at 05:35
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical...

at 05:30
Blockbuster growth in weight-loss drugs was the main driver of a 13.5% increase in spending on prescription medications in the U.S. in 2023, according to ASHP's (American Society of Health-System Pharmacists) report, National Trends in Prescription...

at 05:26
Renowned orthopedic surgeon Dr. Dror Paley, in partnership with Dr. León Mora and the Cora Group Excellence Center for Orthopedic Reconstructive and Limb Lengthening Surgery, is...

at 05:15
The Industrial Technology Research Institute (ITRI) triumphed at the recent Edison Awardstm in Fort Myers, Florida, securing recognition for four exceptional technological breakthroughs: the Novel Dual-Targeted Therapy for Glaucoma, Key Functional...

at 05:00
The Beta-Glucan Market is estimated at USD 542 million in 2024 and is projected to reach USD 800 million by 2029, at a CAGR of 8.1% from 2024 to 2029 according to a report published by MarketsandMarketstm. The growth of the beta-glucan market is...

at 05:00
Geekplus, the global leader in mobile robot and smart logistics solutions, has deployed the first Shelf-to-Person PopPick project in the Nordics for one of the biggest online pharmacy wholesalers in the region, Med24.dk. System Teknik partnered on...



News published on and distributed by: